Display options
Cite
Wang HL, Lu X, Yang X, et al. Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis. Gastroenterol Res Pract. 2016;2016:3435965doi: 10.1155/2016/3435965.
Wang, H. L., Lu, X., Yang, X., & Xu, N. (2016). Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis. Gastroenterology research and practice, 20163435965. https://doi.org/10.1155/2016/3435965
Wang, Hui-Lian, et al. "Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis." Gastroenterology research and practice vol. 2016 (2016): 3435965. doi: https://doi.org/10.1155/2016/3435965
Wang HL, Lu X, Yang X, Xu N. Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis. Gastroenterol Res Pract. 2016;2016:3435965. doi: 10.1155/2016/3435965. Epub 2016 Sep 08. PMID: 27672391; PMCID: PMC5031861.
Copy Download .nbib Format: NLM
Share it on

Gastroenterol Res Pract. 2016;2016:3435965. doi: 10.1155/2016/3435965. Epub 2016 Sep 08.

Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis.

Gastroenterology research and practice

Hui-Lian Wang, Xi Lu, Xudong Yang, Nan Xu

Affiliations

  1. Department of Genetics and Molecular Biology, Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi 710061, China; Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education, Xi'an, Shaanxi 710061, China.
  2. School of Mechanical Engineering, Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China.
  3. 2nd Affiliated Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi 710004, China.

PMID: 27672391 PMCID: PMC5031861 DOI: 10.1155/2016/3435965

Abstract

The relative efficacy of different strategies for chronic hepatitis B (CHB) patients with lamivudine resistance (LAM-R) has not yet been systematically studied. Clinical trials were searched in PUBMED, MEDLINE, EMBASE, and CNKI databases up to February 15, 2016. Nine trials including 764 patients met the entry criteria. In direct meta-analysis, TDF showed a stronger antiviral effect than any one of ETV, LAM/ADV, and ADV against LAM-R hepatitis B virus. LAM/ADV therapy was superior to ADV in suppressing viral replication. ETV achieved similar rate of HBV DNA undetectable compared to ADV or LAM/ADV. In network meta-analysis, TDF had higher rates of HBV DNA undetectable compared to ETV (OR, 24.69; 95% CrI: 5.36-113.66), ADV (OR, 37.28; 95% CrI: 9.73-142.92), or LAM/ADV (OR, 21.05; 95% CrI: 5.70-77.80). However, among ETV, ADV, and LAM/ADV, no drug was clearly superior to others in HBV DNA undetectable rate. Moreover, no significant difference in the rate of ALT normalization or HBeAg loss was observed compared the four rescue strategies with each other. TDF appears to be a more effective rescue therapy than LAM/ADV, ETV, or ADV. LAM plus ADV therapy was a better treatment option than ETV or ADV alone for patients with LAM-R.

References

  1. Hepatology. 2006 Jun;43(6):1385-91 - PubMed
  2. Virol J. 2009 Oct 09;6:163 - PubMed
  3. Dig Dis Sci. 2011 Jul;56(7):2130-6 - PubMed
  4. Virus Genes. 2014 Feb;48(1):32-7 - PubMed
  5. Hepatology. 2007 Feb;45(2):507-39 - PubMed
  6. Clin Mol Hepatol. 2014 Sep;20(3):267-73 - PubMed
  7. Hepatol Int. 2008 Jun;2(2):244-9 - PubMed
  8. J Viral Hepat. 2010 Mar;17(3):171-7 - PubMed
  9. J Hepatol. 2009 Feb;50(2):227-42 - PubMed
  10. Aliment Pharmacol Ther. 2011 Oct;34(8):972-81 - PubMed
  11. J Med Virol. 2010 Nov;82(11):1835-42 - PubMed
  12. Arab J Gastroenterol. 2014 Mar;15(1):1-5 - PubMed
  13. Hepatology. 2009 May;49(5 Suppl):S112-21 - PubMed
  14. Hepatogastroenterology. 2012 Mar-Apr;59(114):477-80 - PubMed
  15. Hepatol Int. 2012 Jun;6(3):531-61 - PubMed
  16. Hepatology. 2014 Feb;59(2):434-42 - PubMed
  17. Korean J Intern Med. 2015 Jan;30(1):32-41 - PubMed
  18. Antimicrob Agents Chemother. 2013 Apr;57(4):1790-6 - PubMed
  19. J Hepatol. 2012 Jul;57(1):167-85 - PubMed
  20. J Gastroenterol Hepatol. 2010 Aug;25(8):1374-80 - PubMed
  21. Clin Ther. 2013 Dec;35(12):1997-2006 - PubMed
  22. Ann Intern Med. 2013 Jul 16;159(2):130-7 - PubMed
  23. PLoS One. 2014 Jun 06;9(6):e98865 - PubMed
  24. Hepatol Int. 2008 Sep;2(3):263-83 - PubMed
  25. J Hepatol. 2006 Feb;44(2):283-90 - PubMed
  26. Hepatology. 2007 Feb;45(2):307-13 - PubMed
  27. World J Gastroenterol. 2015 Mar 7;21(9):2746-53 - PubMed
  28. Gastroenterology. 2003 Dec;125(6):1714-22 - PubMed

Publication Types